NewAmsterdam Pharma (NAMS) Equity Ratio (2022 - 2025)
Historic Equity Ratio for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to 0.93.
- NewAmsterdam Pharma's Equity Ratio rose 732.16% to 0.93 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.93, marking a year-over-year increase of 732.16%. This contributed to the annual value of 0.88 for FY2024, which is 544.44% up from last year.
- Latest data reveals that NewAmsterdam Pharma reported Equity Ratio of 0.93 as of Q3 2025, which was up 732.16% from 0.96 recorded in Q2 2025.
- NewAmsterdam Pharma's Equity Ratio's 5-year high stood at 0.96 during Q2 2025, with a 5-year trough of 0.73 in Q2 2023.
- Over the past 4 years, NewAmsterdam Pharma's median Equity Ratio value was 0.87 (recorded in 2024), while the average stood at 0.87.
- Per our database at Business Quant, NewAmsterdam Pharma's Equity Ratio crashed by 884.25% in 2023 and then soared by 1917.85% in 2024.
- Over the past 4 years, NewAmsterdam Pharma's Equity Ratio (Quarter) stood at 0.91 in 2022, then dropped by 8.84% to 0.83 in 2023, then rose by 5.44% to 0.88 in 2024, then rose by 5.67% to 0.93 in 2025.
- Its Equity Ratio was 0.93 in Q3 2025, compared to 0.96 in Q2 2025 and 0.95 in Q1 2025.